Celularity Inc. has 6 Schedule 13D or 13G filings on record since 2025-07-28. 2 holders' latest filing reports 5% or more of class a common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Dragasac Limited | 41% | 6,335,630 | SCHEDULE 13D/A, 2025-07-28 | 2025-07-24 |
| Philip & Daniele Barach Family Trust | 15.8% | 5,514,686 | SCHEDULE 13D/A, 2026-06-23 | 2026-06-19 |
| Lincoln Alternative Strategies LLC | 0% | 0 | SCHEDULE 13G/A, 2026-02-11 | 2025-07-14 |
Purpose of Transaction (Item 4)
Dragasac Limited
Item 4 of the Schedule 13D is hereby amended and supplemented as follows: Pursuant to the terms agreed upon in the binding term sheet ("Term Sheet") between the Issuer and RWI dated February 12, 2025, RWI agreed to, among other things, an extension of that certain second forbearance agreement dated as of March 13, 2024. Specifically, RWI agreed not to exercise its rights and remedies upon the occurrence of any default under the second amended and restated senior secured loan agreement dated as of January 12, 2024 until an amendment is entered into between the Issuer and RWI whereby the maturity date of the following loans is extended to February 15, 2026: (i) an initial loan in the aggregate principal amount of $6,000,000, (ii) a second loan in the aggregate principal amount of $6,000,000, and (iii) a third loan in the aggregate principal amount of $15,000,000, net of an original issue discount amount equal to $3,750,000. As agreed upon in the Term Sheet, on July 24, 2025, the exercise price of each of the following warrants was adjusted to $2.844 per Common Share, which represents a 10% discount from the closing price of the Issuer's Common Shares on July 24, 2025: (i) the RWI Warrant to purchase 300,000 Common Shares (as adjusted for the Reverse Stock Split) issued to RWI in June 2023, (ii) the Tranche 2 Warrants to purchase 1,350,000 Common Shares (as adjusted for the Reverse Stock Split) issued to RWI in January 2024, and (iii) the Forbearance Warrant to purchase …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-07-28; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-28 | Dragasac Limited | 41% | SCHEDULE 13D/A |
| 2025-08-27 | Lincoln Alternative Strategies LLC | 5.14% | SCHEDULE 13G |
| 2026-02-11 | Lincoln Alternative Strategies LLC | 0% | SCHEDULE 13G/A |
| 2026-04-03 | Philp & Daniele Barach Family Trust | 9.56% | SCHEDULE 13D |
| 2026-04-22 | Philip & Daniele Barach Family Trust | 20.1% | SCHEDULE 13D/A |
| 2026-06-23 | Philip & Daniele Barach Family Trust | 15.8% | SCHEDULE 13D/A |
Tools for this story
Each opens in a new tab, filled in for Celularity Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.